Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Covert Hepatic Encephalopathy Clinical Trial

Official title:
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study

Status Completed

Clinical Trial Summary

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03077217
Study type	Interventional
Source	Shanghai Changzheng Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	May 1, 2017
Completion date	May 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06367127` - Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
Withdrawn	`NCT05189834` - GELSECTAN® and Covert Hepatic Encephalopathy	N/A
Completed	`NCT03585257` - HEAL STUDY (Hepatic Encephalopathy and Albumin Study)	Phase 2